{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-25-000104","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2025-10-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.443798+00:00","generated_at":"2026-05-17T04:18:27.359520+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"confidence":"high","headline":"Cartesian Therapeutics appoints June Seymour as Chief Accounting Officer effective Oct 27, 2025","bullets":["Annual base salary of $385,000; eligible for annual performance bonus targeted at 35% of base salary.","Receives $80,000 sign-on bonus and option to purchase 50,000 shares vesting over four years.","Ms. Seymour most recently served as SVP, Finance and Accounting at DNAnexus; previously VP Finance at Neogene Therapeutics.","CFO Blaine Davis continues as both principal financial officer and principal accounting officer.","Employment agreement includes six-month severance (base salary and pro-rata bonus) and 12-month non-compete."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-25-000104","json":"https://secwatch.observer/filing/0001453687-25-000104.json","markdown":"https://secwatch.observer/filing/0001453687-25-000104.md","text":"https://secwatch.observer/filing/0001453687-25-000104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000104/0001453687-25-000104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000104/rnac-20251002.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:18:27.359520+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}